Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

计划入组 296 人 · 首次发布于 2018 年 10 月 25 日

Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS

计划入组 9 人 · 首次发布于 2018 年 4 月 12 日

Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma

计划入组 19 人 · 首次发布于 2015 年 8 月 28 日

SOS1 / KRAS (KRAS -driven cancer)

anti-KRAS

exoASO-NRAS

Kura Oncology

United States

LABORATOIRE HRA PHARMA

Spain

HRA Pharma America, Inc.

United States

Cogent Biosciences Unveils Promising KRAS Inhibitor Data with Superior Efficacy Profile

BridgeBio Oncology's BBO-11818 Shows Promise as Broad-Spectrum KRAS Inhibitor in Preclinical Studies

Kura Oncology Poised for Growth with Promising Zifto Data and Strong Financials